Agios Pharmaceuticals, Inc. (AGIO)
Agios is a biopharmaceutical company that sells mitapivat and develops other medicines for rare diseases, mainly blood disorders. It last closed at $29.89 on Nov 17, down 0.86% on the day. AGIO reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 3 analysts is $49.00 (+63.9% from the last close), with a high of $62.00 and a low of $35.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in AGIO, 0% of them bullish and 100% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From AGIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on AGIO in the past 90 days. The average target is $49.00, with a high of $62.00 and a low of $35.00, compared with the last close of $29.89.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 6 | Truist Securities | Target lowered | Buy | $37 → $35 |
| Nov 6 | HC Wainwright & Co. | Target raised | Buy | $55 → $62 |
| Oct 29 | HC Wainwright & Co. | Assumed coverage | Buy | $55 |
| Oct 7 | Truist Securities | Target lowered | Buy | $39 → $37 |
| Sep 21 | B of A Securities | Target raised | Buy | $46 → $50 |
Technical Analysis
The stock is 11% below its 20 day and 10% below its 50 day average. It is 7% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the swing low (Oct 30) at $29.80, and the nearest resistance the swing high (May 28) at $30.53.
| RSI (14) | 41.30 | Middle of its range | Neutral |
| MACD | -0.82 | Below its signal line | Bearish |
| Stochastic | 26.8 | Middle of its range | Neutral |
| ADX (14) | 20.5 | Weak trend | |
| Williams %R | -79.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -75.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −4.2% | Change over 10 sessions | Bearish |
| ATR (14) | $1.78 | Typical daily range, 6.0% of price |
| RSI (14) | 45.50 | Middle of its range | Neutral |
| MACD | -0.37 | Below its signal line | Bearish |
| Stochastic | 24.6 | Middle of its range | Neutral |
| ADX (14) | 12.4 | No clear trend | |
| Williams %R | -79.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -115.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −11.0% | Change over 10 sessions | Bearish |
| ATR (14) | $3.95 | Typical daily range, 13.2% of price |
What happened before
See how AGIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How AGIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
Whale Options Flow
90DNo whale options trades in AGIO in the last 90 days.
AGIO Institutional Ownership
Full report →- ▲129 buying vs 96 selling
- ▲Held by funds +2.0 pts
- ▲Funds holding +5
- ▲Superinvestors: 3 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 243 | 238 | +2.1% |
| In funds' top 10 | 3 | 6 | −50.0% |
| Held by funds | 112.5% | 110.5% | +2.0 pts |
| New / increased | 34 / 95 | 36 / 97 | −3.0% |
| Reduced / sold out | 67 / 29 | 63 / 33 | 0.0% |
| Put/call ratio | 0.02 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AGIO is in one of them and how their past AGIO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AGIO in an article yet. Here's the latest on the wider market.
AGIO Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Aug 20, 2026 | Sep 11, 2026 | 22 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Mar 3, 2026 | Apr 7, 2026 | 35 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Dec 11, 2025 | Jan 12, 2026 | 32 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Apr 17, 2025 | May 6, 2025 | 19 d |
| Gilbert CisnerosD · CA | Buy | $1K – $15K | Jan 29, 2025 | Feb 11, 2025 | 13 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Agios Pharmaceuticals
Agios is a biopharmaceutical company that focuses on rare diseases, with a foundation in hematology, the study of blood disorders. Its lead medicine, mitapivat, is sold under the brand names AQVESME and PYRUKYND and is approved to treat anemia in adults with certain rare blood disorders. The company is also developing additional medicines for rare blood and metabolic conditions. Agios is based in Cambridge, Massachusetts, and serves patients and the clinicians who treat them.
- Headquarters
- Cambridge, MA
- Founded
- 2008
- Website
- agios.com ↗





